Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ONXX -- Ignore unavailable to you. Want to Upgrade?

To: Charles Tutt who wrote (630)	9/23/2000 11:58:29 AM
From: Mama Bear	Read Replies (2) \| Respond to of 810

"Come back when a product is imminent and see what a share will cost you." Assuming that you change the word 'when' to the word 'if' the same argument be made of any development stage biotech. Or almost any development stage company. They're all going to be the next _____. Unless one has specialized knowledge of the industry it makes much more sense to wait until the odds are much improved, especially with a company that has a limited pipeline. If the clinicals fail, the stock is toast. Take a look at CLPA on Monday to witness the carnage of a company with a limited pipeline which gets a non-approvable letter from the FDA. An alternative is to pay someone who understands the industry intimately. That's how I get my exposure to development stage biotechs. My strategy also allows me to have a small portion of my money in private biotech companies. Of course a diversified portfolio of development stage biotechs could pay off with above average returns. But you still need some edge to weed out as many of the losers as you can. Buying ONXX without an edge at this time is gambling, IMO. Especially in the face of those with an edge lining up to sell. Even if the bet pays off in the future, it won't prove it wasn't gambling. Regards, Barb

To: Charles Tutt who wrote (630)	9/23/2000 2:57:07 PM
From: Tom Hua	Read Replies (2) \| Respond to of 810

Charles, I don't know if you followed the biotech industry in the early 90s. There were literally more than 1000 biotech startups, many came public during that time, most claimed to be working on a cure for cancer. A few years later, 9 out of 10 closed doors after money ran out and shareholders were left holding some expensive wallpapers. No cure for cancer of course, just a pipe dream. In the remote chance that ONXX will be successful with its endeavor, it's no cure for cancer either. The patients will eventually die, only with fewer tumors. Regards, Tom

To: Charles Tutt who wrote (630)	9/23/2000 3:28:44 PM
From: lifeisgood	Read Replies (1) \| Respond to of 810

Come back when a product is imminent and see what a share will cost you. Nobody is forcing you to buy now. When a product is imminent, I just may be a buyer. In the mean time, I think I'll follow the lead of people who should know what they're doing and sell the stock. My argument is that a fundamental case cannot be made for ONXX. For example, what fundamental basis is there for the stock to be valued at $20? Why not $2000 or $20000. After all, if ONXX somehow rids mankind of cancer, every share would be worth 20K. At some point, one has to look at the possible worth of the company based on products or prospects. In this regard, either insiders are mindless fools who are selling their fortunes away or longs are unrealistically optimistic. I'm putting my money on the insiders. best... LIG